A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB0024 in Adult Patients With Idiopathic Pulmonary Fibrosis
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Simtuzumab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Gilead Sciences
- 02 Dec 2013 Extension study details added and added as a related profile.
- 30 Nov 2013 New trial record